CANDIN
HPV-associated Verruca Vulgaris (Common Warts)
Phase 3Active
Key Facts
Indication
HPV-associated Verruca Vulgaris (Common Warts)
Phase
Phase 3
Status
Active
Company
About Nielsen BioSciences
Nielsen BioSciences is a commercial-stage biotech with a unique focus on delayed-type hypersensitivity (DTH) skin test antigens for assessing cell-mediated immunity. The company has two approved diagnostic products: CANDIN for Candida albicans sensitivity and SPHERUSOL for Coccidioides immitis (Valley Fever) exposure. Leveraging its DTH platform, Nielsen is pursuing therapeutic applications, most notably a Phase 3 investigational program using CANDIN to treat HPV-associated common warts. As a private company, it operates in niche immunology markets with potential for expansion into broader immunotherapy.
View full company profile